Introduction
============

Persisting pain has been proposed to result from a gene environment interaction where nerve injuries or inflammatory processes act as triggers while the clinical symptoms develop only in a minority of subjects ([@B125]). A role of the genetic background in pain is supported by evidence of many variants modulating the individual perception of pain and the development of its persistence ([@B42]; [@B139]; [@B161]). Genetic variants have been reported to confer protection against pain such as the rs1799971 variant in the μ-opioid receptor gene (*OPRM1*) ([@B146]), or to increase the risk for persisting pain such as the rs12584920 variant of the 5-hydroxytryptamine receptor 2A gene (*HTR2A*) ([@B166]) or the rs734784 polymorphism in the voltage-gated potassium ion channel modifier, subfamily S member 1, gene (*KCNS1*) ([@B34]). Nevertheless, the genetic background of persisting pain is still incompletely understood ([@B160]; [@B142]) and under intense discussion.

Until recently, research focused on the role of selected functional genetic variants as protective or risk factors of persisting pain. This has changed with the broader availability of next generation sequencing (NGS) ([@B155]). To make use of these technical advancements, we developed a custom AmpliSeq^TM^ library and sequencing assay for efficient detection of genetic variants possibly associated with persisting pain. We propose an assay of a set of 77 genes supported by evidence of an involvement in pain and its development toward persistence. The set size fully uses the technical specifications of the AmpliSeq^TM^ gene sequencing library technique.

Materials and Methods {#s1}
=====================

Selection of Genes Relevant for Persisting Pain
-----------------------------------------------

A set of candidate genes with shown or biologically plausible relevance to persisting pain was created by applying a combination of criteria, which provided three different genetic subsets. **Subset 1** was chosen exclusively on the basis of computational functional genomics based on a recently published analysis of persisting pain regarded as displaying systemic features of learning and neuronal plasticity ([@B149]). As discussed previously ([@B231]), the view of chronic pain as a dysregulation in biological processes of learning and neuronal plasticity ([@B4]) seems to be captured by the controlled vocabulary ([@B19]) of the Gene Ontology (GO) knowledge base by the GO terms "learning or memory" (GO:0007611)^[1](#fn01){ref-type="fn"}^ and "nervous system development" (GO:0007399)^[2](#fn02){ref-type="fn"}^. An intersection of the genes annotated to these GO terms with a set of 539 "pain genes" identified empirically as relevant to pain provided the first subset of 34 genes described in detail previously ([@B231]). Briefly, the intersecting set of so-called "pain genes" consists of a combination of (i) genes listed in the PainGenes database ([@B121])^[3](#fn03){ref-type="fn"}^, (ii) genes causally involved in human hereditary diseases associated with extreme pain phenotypes, (iii) genes found to be associated with chronic pain in at least three human studies, and (iv) genes coding for targets of novel analgesics under clinical development ([@B137]).

**Subset 2** consisted of genes that were reported to carry variants modulating the risk or the phenotypic symptoms in at least two different clinical settings of persisting pain. They were obtained using (i) a PubMed database search for the string "(chronic OR persisting OR neuropathic OR back OR inflammatory OR musculoskeletal OR visceral OR widespread OR idiopathic OR fibromyalgia) AND pain AND (polymorphism OR variant) NOT review," to which genes highlighted in overviews on pain genetics (e.g., [@B53]) were added. The intersection of the queried genes with the set of 539 "pain genes" (see above) provided a subset of 13 genes (**Table [1](#T1){ref-type="table"}**).

###### 

Genes included in the proposed NGS panel of persisting pain, combined from three subsets included on different bases.

  Gene symbol      NCBI    Gene description                                                     Reference
  ---------------- ------- -------------------------------------------------------------------- -----------
  **Subset \#1**                                                                                
  *ADCY1*          107     Adenylate cyclase 1                                                  [@B234]
  *BDNF*           627     Brain-derived neurotrophic factor                                    [@B169]
  *CDK5*           1020    Cyclin-dependent kinase 5                                            [@B248]
  *CHRNB2*         1141    Cholinergic receptor, nicotinic, beta 2                              [@B44]
  *CNR1*           1268    Cannabinoid receptor 1 (brain)                                       [@B214]
  *DLG4*           1742    Disks, large homolog 4 (Drosophila)                                  [@B60]
  *DRD1*           1812    Dopamine receptor D1                                                 [@B174]
  *DRD2*           1813    Dopamine receptor D2                                                 [@B174]
  *DRD3*           1814    Dopamine receptor D3                                                 [@B182]
  *EGR1*           1958    Early growth response 1                                              [@B113]
  *FOS*            2353    Cellular oncogene FOS                                                [@B1]
  *FYN*            2534    Src family tyrosine kinase                                           [@B133]
  *GABRA5*         2558    GABA A receptor, alpha 5                                             [@B13]
  *GALR2*          8811    Galanin receptor 2                                                   [@B93]
  *GRIN1*          2902    Glutamate receptor, NMDA 1                                           [@B180]
  *GRIN2A*         2903    Glutamate receptor, NMDA 2A                                          [@B180]
  *GRIN2B*         2904    Glutamate receptor, NMDA 2B                                          [@B180]
  *GRM5*           2915    Glutamate receptor, metabotropic 5                                   [@B238]
  *HRH3*           11255   Histamine receptor H3                                                [@B92]
  *KIT*            3815    Tyrosine kinase KIT                                                  [@B223]
  *NF1*            4763    Neurofibromin 1                                                      [@B245]
  *NGF*            4803    Nerve growth factor                                                  [@B118]
  *NTF4*           4909    Neurotrophin 4                                                       [@B118]
  *NTRK1*          4914    Neurotrophic tyrosine kinase 1                                       [@B118]
  *OXT*            5020    Oxytocin prepropeptide                                               [@B73]
  *PLCB1*          23236   Phospholipase C, beta 1                                              [@B208]
  *PRKCG*          5582    Protein kinase C, gamma                                              [@B213]
  *PRNP*           5621    Prion protein                                                        [@B64]
  *PTN*            5764    Pleiotrophin                                                         [@B75]
  *PTPRZ1*         5803    Protein tyrosine phosphatase Z 1                                     [@B231]
  *RELN*           5649    Reelin                                                               [@B15]
  *S100B*          6285    S100 calcium binding protein B                                       [@B251]
  *SLC6A4*         6532    Serotonin transporter                                                [@B172]
  *TH*             7054    Tyrosine hydroxylase                                                 [@B12]
  **Subset \#2**                                                                                
  *ADRB2*          154     Adrenoceptor beta 2                                                  [@B87]
  *COMT*           1312    Catechol-*O*-methyltransferase                                       [@B58]
  *ESR1*           2099    Extrogen Receptor 1                                                  [@B188]
  *GCH1*           2643    GTP cyclohydrolase 1                                                 [@B224]
  *IL1B*           3553    Interleukin 1B                                                       [@B136]
  *IL4*            3565    Interleukin 4                                                        [@B222]
  *IL6*            3569    Interleukin 6                                                        [@B209]
  *IL10*           3586    Interleukin 10                                                       [@B221]
  *P2RX7*          5027    Purinergic Receptor P2X7                                             [@B220]
  *SCN9A*          6335    Sodium voltage-gated alpha subunit 9                                 [@B186]
  *SOD2*           6648    Superoxide dismutase 2                                               [@B202]
  *TNF*            7124    Tumor necrosis factor                                                [@B126]
  *TRPV1*          7442    Transient receptor potential cation channel, subfamily V, member 1   [@B11]
  **Subset \#3**                                                                                
  *ABHD12*         26090   Abhydrolase domain containing 12                                     [@B109]
  *ABHD16A*        7920    Abhydrolase domain containing 16A                                    [@B109]
  *ABHD6*          57406   Abhydrolase domain containing 6                                      [@B109]
  *CACNG2*         10369   Calcium voltage-gated channel auxiliary subunit gamma 2              [@B167]
  *CSF1*           1435    Colony stimulating factor 1                                          [@B225]
  *DRD4*           1815    Dopamine receptor D4                                                 [@B16]
  *FAAH*           2166    Fatty acid amide hydrolase                                           [@B99]
  *FKBP5*          2289    Fk506 binding protein 5                                              [@B63]
  *GDNF*           2668    Glial cell derived neurotrophic factor                               [@B191]
  *GFRA1*          2674    GDNF family receptor alpha 1                                         [@B247]
  *GPR132*         29933   G protein-coupled receptor 132                                       [@B89]
  *HCN2*           610     Hyperpolarization-activated cyclic nucleotide-gated                  [@B229]
  *HLA-DQB1*       3119    Major histocompatibility complex, class II, DQ beta 1                [@B48]
  *HLA-DRB1*       3123    Major histocompatibility complex, class II, DR beta 1                [@B48]
  *HTR1A*          3350    5-hydroxytryptamine (serotonin) receptor 1A                          [@B130]
  *HTR2A*          3356    5-hydroxytryptamine (serotonin) receptor 2A                          [@B166]
  *IL1R2*          7850    Interleukin 1 receptor type 2                                        [@B221]
  *KCNS1*          3787    Potassium voltage-gated channel, modifier subfamily S, member 1      [@B34]
  *LTB4R*          1241    Leukotriene b4 receptor                                              [@B253]
  *LTB4R2*         56413   Leukotriene b4 receptor 2                                            [@B253]
  *OPRD1*          4985    Opioid receptor delta 1                                              [@B123]
  *OPRK1*          4986    Opioid receptor kappa 1                                              [@B77]
  *OPRM1*          4988    Opioid receptor mu 1                                                 [@B141]
  *RET*            5979    RET receptor tyrosine kinase                                         [@B215]
  *RUNX1*          861     Runt related transcription factor 1                                  [@B24]
  *TLR4*           7099    Toll like Receptor 4                                                 [@B94]
  *TRPA1*          8989    Transient receptor potential cation channel, subfamily A, member 1   [@B11]
  *TRPM8*          79054   Transient receptor potential cation channel, subfamily M, member 8   [@B11]
  *TRPV4*          59341   Transient receptor potential cation channel, subfamily V, member 4   [@B11]
  *TSPO*           706     Translocator protein                                                 [@B134]

Subset \#1 comprises

d

= 34 genes that had resulted from a computational functional genomics analysis (

Ultsch et al., 2016

) pursuing the hypothesis that persisting pain displays systemic features of learning and neuronal plasticity (

Mansour et al., 2014

). Hence, from a set of genes identified empirically as relevant to pain and listed in the PainGenes database (

http://www.jbldesign.com/jmogil/enter.html

,

Lacroix-Fralish et al., 2007

), those were selected that are annotated to the Gene Ontology (

Ashburner et al., 2000

) terms "learning or memory" and "nervous system development." The references are those found to provide evidence for an association with pain, except for PTPRZ1 that was a novel finding in (

Ultsch et al., 2016

). Subset \#2 comprises

d

= 13 genes identified empirically as relevant to pain and listed in the PainGenes database (

http://www.jbldesign.com/jmogil/enter.html

,

Lacroix-Fralish et al., 2007

) and reported to carry variants that modulated the risk or the symptomatology in at least two different clinical settings of persisting paint. Subset \#3 comprises

d

= 30 genes repeatedly shown during the last several years to play a role in the human genetics of persisting pain or recently reported as novel players.

Finally, **subset 3** comprised genes that have consistently been included in human pain research projects over the last several years. One of them is the *OPRM1* gene that codes for the human μ-opioid receptor and which has been shown to modulate the time course of persisting cancer pain by delaying the necessity of opioid treatment ([@B143]). However, further genes were added such as the *GDNF* gene coding for the glial cell derived neurotrophic factor, which has been shown to be involved in a glia-dependent mechanism of neuropathic pain ([@B240]) although no modulating human genetic variants have been reported so far. Following expert counseling within the EU-funded "glial-opioid interface in chronic pain, GLORIA" research consortium ([@B115])^[4](#fn04){ref-type="fn"}^, a subset of 30 genes (**Table [1](#T1){ref-type="table"}**) was identified. Thus, the complete set as the union of the three subsets comprised 43 + 13 + 30 = 77 genes that are proposed to be included in an NGS panel of human persisting pain.

DNA Sample Origin
-----------------

Due to the costs of assay development (for details, see second paragraph of the Discussion), the Ampliseq^TM^ panel was established in a limited number of *n* = 72 DNA samples. This corresponds to the number of samples used in comparable recent studies for NGS assay establishment and validation ([@B14]; [@B38]; [@B162]; [@B205]). To further limit the project costs, the Ampliseq^TM^ panel was established in a subset of samples originating from a clinical cohort of 1,000 women who had undergone breast cancer surgery ([@B104]; [@B144]). The study followed the Declaration of Helsinki and was approved by the Coordinating Ethics Committee of the Helsinki University Hospital. Each participating subject had provided a written informed consent including genetic studies.

Specifically, for the presently reported method establishment, a subsample of 72 women (age 58.4 ± 8 years, mean ± standard deviation, weight 69.3 ± 11 kg), was drawn from the clinical subgroup not having developed persisting pain during the observation period. This was believed to come closer to a random sample than a mixture of patients with persisting and without persisting pain. This limitation of the sample selection has probably affected which and how many variants were identified. However, it is unlikely to have jeopardized the general applicability of the gene selection heuristics, assay establishment and validation, and of the functional analysis of the selected subset of genes.

DNA Template Preparation and Amplification
------------------------------------------

A multiplex PCR amplification strategy for the coding gene sequences was accomplished online (Ion Ampliseq^TM^ Designer)^[5](#fn05){ref-type="fn"}^ to amplify the target region specified above (for primer sequences, see **Supplementary Table [1](#SM1){ref-type="supplementary-material"}**) with 25 base pair exon padding. After a comparison of several primer design options, the design providing the maximum target sequence coverage was chosen. The ordered 1,953 amplicons covered approximately 97.5% of the target sequence (**Supplementary Table [2](#SM2){ref-type="supplementary-material"}**). A total of 10 ng DNA per sample was used for the target enrichment by a multiplex PCR and each DNA pool was amplified with the Ion Ampliseq^TM^ Library Kit in conjunction with the Ion Ampliseq^TM^ "custom Primer Pool"-protocols according to the manufacturer's procedures (Life Technologies, Darmstadt, Germany).

After each pool had undergone 18 PCR cycles, the PCR primers were removed with FuPa Reagent and the amplicons were ligated to the sequencing adaptors with short stretches of index sequences (barcodes) that enabled sample multiplexing for subsequent steps (Ion Xpress^TM^ Barcode Adapters Kit; Life Technologies). After purification with AMPure XP beads (Beckman Coulter, Krefeld, Germany), the barcoded libraries were quantified with a Qubit^®^ 2.0 Fluorimeter (Life Technologies, Darmstadt, Germany) and normalized for DNA concentration to a final concentration of 20 pmol/l using the Ion Library Equalizer^TM^ Kit (Life Technologies, Darmstadt, Germany). Equalized barcoded libraries from seven to eight samples at a time were pooled. To clonally amplify the library DNA onto the Ion Sphere Particles (ISPs; Life Technologies, Darmstadt, Germany), the library pool was subjected to emulsion PCR by using an Ion PGM HI-Q View Template Kit on an PGM OneTouch system (Life Technologies, Darmstadt, Germany) following the manufacturer's protocol.

Sequencing
----------

Enriched ISPs which carried many copies of the same DNA fragment were subjected to sequencing on an Ion 318 Chip to sequence pooled libraries with seven to eight samples. During this process, bases are inferred from light intensity signals, a process commonly referred to as base-calling ([@B124]). The number of combined libraries that can be accommodated in a single sequencing run depends on the size of the chip, the balance of barcoded library concentration, and the coverage required. The high-capacity 318 chip was chosen (instead of the low-capacity 314 or the medium-capacity 316 chip) to obtain a high sequencing depth of coverage for a genomic DNA library with \>95% of bases at 30x. Sequencing was performed using the sequencing kit (Ion PGM Hi-Q Sequencing Kit; Life Technologies, Darmstadt, Germany) as per the manufacturer's instructions with the 200 bp single-end run configuration. This kit contained the most advanced sequencing chemistry available to users of the Ion PGM System (Life Technologies, Darmstadt, Germany).

Data Analysis
-------------

### Bioinformatics Generation of Sequence Information

The raw data (unmapped BAM-files) from the sequencing runs were processed using Torrent Suite Software (Version 5.2.2, Life Technologies, Darmstadt, Germany) to generate read alignments which were filtered by the software into mapped BAM-files using the reference genomic sequence (hg19) of target genes. Variant calling was performed with the Torrent Variant Caller Plugin using as key parameters: minimum allele frequency = 0.15, minimum quality = 10, minimum coverage = 20 and minimum coverage on either strand = 3.

The annotation of called variants was done using the Ion Reporter Software (Version 4.4; Life Technologies, Darmstadt, Germany) for the VCF files that contained the nucleotide reads and the GenomeBrowse^®^ software (Version 2.0.4, Golden Helix, Bozeman, MT, United States) to map the sequences to the reference sequences GRCh37 hg19 (dated February 2009). The SNP and Variation Suite software (Version 8.4.4; Golden Helix, Bozeman, MT, United States) was used for the analysis of sequence quality, coverage and for variant identification.

Based on the observed allelic frequency, the expected number of homozygous and heterozygous carriers of the respective SNP (single nucleotide polymorphism) was calculated using the Hardy-Weinberg equation. Only variants within the Hardy-Weinberg equilibrium as assessed using Fisher's exact test ([@B54]) were retained. The SNP and Variation Suite software (Version 8.4.4; Golden Helix, Bozeman, MT, United States) was used for the analysis of sequence quality, coverage and for variant identification.

Assay Validation
----------------

Method validation was accomplished by means of Sanger sequencing ([@B192]; [@B193]) in an independent external laboratory (Eurofins Genomics, Ebersberg, Germany). As performed previously with different AmpliSeq^TM^ panels ([@B116]) and other genotyping assays ([@B211], [@B212]), four DNA samples have been chosen randomly from an independent cohort of healthy subjects and sequenced with the current NGS panel. For the detected variant type, single nucleotide polymorphisms from five different genomic regions for which clinical associations have been reported (**Table [2](#T2){ref-type="table"}**), i.e., rs324420 (*FAAH*), rs333970 (*CSF1*), rs4986790 (*TLR4)*, rs4633 (*COMT*), and rs17151558 (*RELN*) were chosen for external sequencing. Amplification of the respective DNA segments was done using PCR primer pairs (forward, reverse) of (i) 5′-TTTCTTAAAAAGGCCAGCCTCCT-3′ and 5′-AATGACCCAAGATGCAGAGCA-3′ (ii) 5′-GCCTTCAACCCCGGGATGG-3′ and 5′-CTCCGATCCCTGGTGCTCCTC-3′ (iii) 5′-TTTATTGCACAGACTTGCGGGTTC-3′ and 5′-AGCCTTTTGAGAGATTTGAGTTTCA-3′ (iv) 5′-CCTTATCGGCTGGAACGAGTT-3′ and 5′-GTAAGGGCTTTGATGCCTGGT-3′ (v) 5′-GTTATTCCTCTGTAAGCAGCTGCCT-3′ and 5′-TGTTTGTTTTAGATTGTGGTGGGTT-3′. Results of Sanger sequencing were aligned with the genomic sequence and analyzed using Chromas Lite^®^ (Version 2.1.1, Technelysium Pty Ltd, South Brisbane, QLD, Australia) and the GenomeBrowse^®^ (Version 2.0.4, Golden Helix, Bozeman, MT, United States) was used to compare the sequences obtained with NGS or Sanger techniques.

###### 

A list of coding human variants in the 77 putative chronic pain genes, found in the present random sample of 72 subjects of Caucasian ethnicity, for which clinical associations have been reported.

  Gene                Variant            dbSNP^\#^ accession number   Known clinical association                                     Reference
  ------------------- ------------------ ---------------------------- -------------------------------------------------------------- -----------
  **Pain context**                                                                                                                   
  *FAAH*              1:46870761-SNV     rs324420                     Effect of endocannabinoid degradation on pain                  [@B17]
  *FAAH*              1:46870761-SNV     rs324420                     Cold and heat pain sensitivity                                 [@B107]
  *CSF1*              1:110466338-SNV    rs333970                     Rheumatoid arthritis                                           [@B216]
  *NGF*               1:115829313-SNV    rs6330                       Procedural pain                                                [@B55]
  *NGF*               1:115829313-SNV    rs6330                       Susceptibility to migraine                                     [@B33]
  *IL1B*              2:113590966-SNV    rs1143634                    Adverse effects in postoperative pain                          [@B218]
  *IL1B*              2:113590966-SNV    rs1143634                    Low back pain                                                  [@B57]
  *SCN9A*             2:167099158-SNV    rs6746030                    Pain susceptibility in Parkinson disease                       [@B76]
  *SCN9A*             2:167099158-SNV    rs6746030                    Congenital insensitivity to pain                               [@B111]
  *SCN9A*             2:167099158-SNV    rs6746030                    Basal Pain Sensitivity                                         [@B49]
  *SCN9A*             2:167145122-SNV    rs188798505                  Altered pain perception                                        [@B186]
  *DRD3*              3:113890815-SNV    rs6280                       Acute pain in sickle cell disease                              [@B100]
  *DRD3*              3:113890815-SNV    rs6280                       Higher prevalence of migraine                                  [@B91]
  *ADRB2*             5:148206646-SNV    rs1042717                    Musculoskeletal pain                                           [@B41]
  *ADRB2*             5:148206885-SNV    rs1800888                    Migraine                                                       [@B199]
  *ESR1*              6:152129077-SNV    rs2077647                    Migraine                                                       [@B200]
  *ESR1*              6:152129077-SNV    rs2077647                    Musculoskeletal pain                                           [@B244]
  *OPRM1*             6:154360797-SNV    rs1799971                    Pain of various origins                                        [@B140]
  *SOD2*              6:160113872-SNV    rs4880                       Migraine                                                       [@B176]
  *IL6*               7:22771039-SNV     rs13306435                   Low back pain                                                  [@B56]
  *OPRK1*             8:54142157-SNV     rs702764                     Neuropathic pain                                               [@B66]
  *TLR4*              9:120475302-SNV    rs4986790                    Musculoskeletal pain                                           [@B68]
  *TH*                11:2188238-SNV     rs6357                       Widespread Pain                                                [@B101]
  *TH*                11:2190951-SNV     rs6356                       Migraine                                                       [@B32]
  *BDNF*              11:27679916-SNV    rs6265                       Widespread Pain                                                [@B55]
  *DRD2*              11:113283459-SNV   rs6277                       Post-surgical pain                                             [@B106]
  *DRD2*              11:113283477-SNV   rs6275                       Migraine                                                       [@B173]
  *P2RX7*             12:121600253-SNV   rs208294                     Cold pain sensitivity                                          [@B96]
  *P2RX7*             12:121605355-SNV   rs7958311                    Neuropathic pain                                               [@B232]
  *HTR2A*             13:47409034-SNV    rs6314                       Migraine susceptibility                                        [@B249]
  *TRPV1*             17:3480447-SNV     rs8065080                    Neuropathic pain                                               [@B47]
  *KCNS1*             20:43723627-SNV    rs734784                     Neuropathic pain                                               [@B47]
  COMT                22:19950235-SNV    rs4633                       Postoperative pain                                             [@B105]
  *COMT*              22:19950263-SNV    rs6267                       Widespread Pain                                                [@B129]
  *COMT*              22:19951271-SNV    rs4680                       Altered pain perception                                        [@B241]
  **Other context**                                                                                                                  
  *CSF1*              1:110466466-SNV    rs1058885                    Periodontitis                                                  [@B25]
  *CSF1*              1:110466555-SNV    rs2229165                    Carcinogenesis/breast cancer                                   [@B195]
  *NTRK1*             1:156846233-SNV    rs6334                       Nephropathy                                                    [@B81]
  *NTRK1*             1:156848946-SNV    rs6339                       Acute myeloid leukemia                                         [@B203]
  *SCN9A*             2:167143050-SNV    rs41268673                   Erythromelalgia                                                [@B111]
  *TRPM8*             2:234854550-SNV    rs11562975                   Hyperresponsiveness in bronchial asthma                        [@B164]
  *TRPM8*             2:234905078-SNV    rs11563208                   Anthropometric parameters                                      [@B181]
  *DRD3*              3:113890789-SNV    rs3732783                    Phenotypic traits relevant to anorexia nervosa                 [@B190]
  *KIT*               4:55593464-SNV     rs3822214                    Cancer risk                                                    [@B179]
  *KIT*               4:55602765-SNV     rs3733542                    Glandular odontogenic cyst                                     [@B210]
  *HTR1A*             5:63257483-SNV     rs1799921                    Bipolar disorders                                              [@B74]
  *ADRB2*             5:148206646-SNV    rs1042717                    Cognitive dysfunction in opioid-treated patients with cancer   [@B119]
  *DRD1*              5:174868840-SNV    rs155417                     Alcohol dependence                                             [@B78]
  *HLA-DQB1*          6:32629920-SNV     rs41544112                   Ulcerative colitis                                             [@B2]
  *FKBP5*             6:35544942-SNV     rs34866878                   Clinical response in pediatric acute myeloid leukemia          [@B158]
  *CNR1*              6:88853635-SNV     rs1049353                    Bone mineral density                                           [@B246]
  *CNR1*              6:88853635-SNV     rs1049353                    Alcohol dependence                                             [@B150]
  *CNR1*              6:88853635-SNV     rs1049353                    Nicotine dependence                                            [@B27]
  *CNR1*              6:88853635-SNV     rs1049353                    Obesity                                                        [@B196]
  *CNR1*              6:88853635-SNV     rs1049353                    Psychiatric disorders                                          [@B85]
  *ESR1*              6:152129077-SNV    rs2077647                    Breast cancer susceptibility                                   [@B128]
  *ESR1*              6:152129077-SNV    rs2077647                    Prostate cancer development                                    [@B102]
  *ESR1*              6:152129077-SNV    rs2077647                    Osteoporosis                                                   [@B219]
  *ESR1*              6:152129308-SNV    rs746432                     Mood disorders                                                 [@B156]
  *ESR1*              6:152201875-SNV    rs4986934                    Endometrial cancer risk                                        [@B242]
  *OPRM1*             6:154360508-SNV    rs6912029                    Irritable bowel syndrome                                       [@B18]
  *OPRM1*             6:154360797-SNV    rs1799971                    Schizophrenia                                                  [@B204]
  *OPRM1*             6:154414573-SNV    rs562859                     Depressive disorder                                            [@B67]
  *OPRM1*             6:154414563-SNV    rs675026                     Treatment response for opiate dependence                       [@B3]
  *SOD2*              6:160113872-SNV    rs4880                       Development of type 2 diabetes mellitus                        [@B127]
  *SOD2*              6:160113872-SNV    rs4880                       Breast cancer susceptibility                                   [@B189]
  *SOD2*              6:160113872-SNV    rs4880                       Asthma                                                         [@B250]
  *ADCY1*             7:45703971-SNV     rs1042009                    Bipolar disorder                                               [@B207]
  *RELN*              7:103124207-SNV    rs1062831                    Attention deficit hyperactivity disorder                       [@B120]
  *RELN*              7:103251161-SNV    rs362691                     Childhood epilepsy                                             [@B51]
  *OPRK1*             8:54142154-SNV     rs16918875                   Susceptibility to addiction                                    [@B117]
  *TRPV1*             8:72948588-SNV     rs13280644                   Perception olfactory stimuli                                   [@B201]
  *TLR4*              9:120475602-SNV    rs4986791                    Breast cancer susceptibility                                   [@B157]
  *GRIN1*             9:140051238-SNV    rs6293                       Schizophrenia                                                  [@B70]
  *RET*               10:43610119-SNV    rs1799939                    Hirschsprung's disease                                         [@B233]
  *RET*               10:43615094-SNV    rs1800862                    Medullary thyroid carcinoma                                    [@B22]
  *GFRA1*             10:117884950-SNV   rs2245020                    Age-related macular degeneration                               [@B197]
  *DRD4*              11:637537-Del      rs587776842                  Acousticous neurinoma                                          [@B168]
  *BDNF*              11:27720937-SNV    rs66866077                   Irritable bowel syndrome-diarrhea                              [@B18]
  *DRD2*              11:113283484-SNV   rs1801028                    Neurologic disorders                                           [@B46]
  *GRIN2B*            12:13717508-SNV    rs1806201                    Alzheimer's disease                                            [@B5]
  *TRPV4*             12:110252547-SNV   rs3742030                    Hyponatremia                                                   [@B227]
  *P2RX7*             12:121592689-SNV   rs17525809                   Multiple sclerosis                                             [@B175]
  *HTR2A*             13:47466622-SNV    rs6305                       Susceptibility to substance abuse                              [@B84]
  *LTB4R*             14:24785092-SNV    rs34645221                   Asthma susceptibility                                          [@B230]
  *GABRA5*            15:27182357-SNV    rs140682                     Autism-spectrum disorders                                      [@B88]
  *GRIN2A*            16:9943666-SNV     rs2229193                    Hyperactivity disorder                                         [@B110]
  *DLG4*              17:7099811-SNV     rs17203281                   Schizophrenia                                                  [@B228]
  *SLC6A4*            17:28530193-SNV    rs6352                       Autism-spectrum disorders                                      [@B183]
  *NF1*               17:29553485-SNV    rs2285892                    Neurofibromatosis                                              [@B148]
  *HCN2*              19:607984-SNV      rs3752158                    Risk of depression                                             [@B153]
  *PRKCG*             19:54394965-SNV    rs3745396                    Osteosarcoma susceptibility                                    [@B147]
  *PRNP*              20:4680251-SNV     rs1799990                    Creutzfeldt-Jakob disease                                      [@B154]
  *HRH3*              20:60791422-SNV    rs3787430                    Risk of chronic heart failure                                  [@B83]
  *S100B*             21:48022230-SNV    rs1051169                    Schizophrenia                                                  [@B132]

The selection is restricted to one or two publications per variant, and it focuses on a pain context corresponding to the main aim of the present NGS gene panel; however, functional variants highlighted in another clinical context are additionally provided in the lower part of the table.

\#

Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD, United States): National Center for Biotechnology Information, National Library of Medicine. Available from:

http://www.ncbi.nlm.nih.gov/SNP/

(

Sherry et al., 2001

).

Results
=======

The NGS assay of the proposed set of 77 human genes relevant to persisting pain was established in 72 genomic DNA samples. As applied previously ([@B116]), only exons including 25 bases of padding around all targeted coding regions for which the realized read-depths for each nucleotide was higher than 20 were contemplated as successfully analyzed. With this acceptance criterion the whole or almost whole coverage of the relevant sequences was obtained (**Table [1](#T1){ref-type="table"}**; for details on missing variants, see **Supplementary Table [3](#SM3){ref-type="supplementary-material"}**). The NGS sequencing process of the whole patient cohort required ten separate runs, each with samples of *n* = 7 or *n* = 8 patients. Coverage statistics were analogous between all runs and matched the scope of accepted quality levels \[20--22\]. A median of 2.85 ⋅ 10^6^ reads per run was produced. The mean depth was close to 200 reads, the mean read length of called bases resulted in 205 bases and average chip loading was 71% (**Figure [1A](#F1){ref-type="fig"}**). To establish a sequencing output with a high density of ISPs on a sequencing chip, the chip loading value should exceed 60% (Life Technologies, Carlsbad, United States). The generated results of all NGS runs matched with the results obtained with Sanger sequencing of random samples (**Figure [1B](#F1){ref-type="fig"}**), meaning the accordance of nucleotide sequences between NGS and Sanger sequencing was 100% in all validated samples.

![Assay establishment and validation. **(A)** Pseudo-color image of the Ion 318^TM^ v2 Chip plate showing percent loading across the physical surface. This sequencing run had a 76% loading, which ensures a high Ion Sphere Particles (ISP) density. Every 318 chip contains 11 million wells and the color scale on the right side conduces as a loading indicator. Deep red coloration stays for a 100% loading, which means that every well in this area contains an ISP (templated and non-templated) whereas deep blue coloration implies that the wells in this area are empty. **(B)** Alignment of a segment of the ion torrent sequence of the *COMT* gene as a Golden Helix Genome Browse^®^ readout versus the same sequence according to an externally predicted Sanger electropherogram. Highlighted is the *COMT* variant rs4633 (COMT c.186C\>T → p.His62 =) as a heterozygous mutation and a non-mutated wild type. The SNP is part of the functional *COMT* haplotype comprising rs4633, rs4818 and rs4680, which showed \>11-fold difference in expressed enzyme activity and was reported to be associated with different phenotypes of pain sensitivity ([@B42]).](fphar-09-01008-g001){#F1}

Following elimination of nucleotides agreeing with the standard human genome sequence GRCh37 g1k (dated February 2009), the result of the NGS consisted of a vector of nucleotide information about the *d* = 77 genes for each individual DNA sample (**Figure [2](#F2){ref-type="fig"}**). This vector had a length equaling the set union of the number of chromosomal positions in which a non-reference nucleotide had been found in any probe of the actual cohort. Specifically, a total of 3,185 genetic variants was found, of which 659 were located in coding parts of the genes, 1,241 were located in introns and 1,285 in the 3′-UTR, 5′-UTR, upstream or downstream regions. The coding variants for which a clinical or phenotypic association have been reported are listed in **Table [2](#T2){ref-type="table"}** together with an example of each variant. Most of the observed variants were single nucleotide polymorphisms (*d* = 571) whereas mixed polymorphisms (*d* = 26), nucleotide insertions (*d* = 18) or nucleotide deletions (*d* = 44) were more rarely found.

![Mosaic plot representing a contingency table of the types of genetic variants detected by means of the present AmpliSeq^TM^ panel versus the genes included in the assay. The vertical size of the cells is proportional to the number of variants of a particular type; the horizontal size of the cells is proportional to the number of variants found in the respective gene. The location of the variants is indicated at the left of the mosaic plot in letters colored similarly to the respective bars in the mosaic plot. Variants were not found at all possible locations of each gene, which causes the reduction of several bars to dashed lines drawn as placeholders and indicating that at the particular location no variant has been found in the respective gene. The figure has been created using the R software package (version 3.4.2 for Linux; <http://CRAN.R-project.org/>, [@B184]). UTR: untranslated region. NCExonic: Non-coding exonic.](fphar-09-01008-g002){#F2}

Discussion
==========

In this report, development and validation of a novel Ampliseq^TM^ NGS assay for the coding regions and boundary parts of *d* = 77 genes qualifying as candidate modulators of persisting pain is described. The NGS assay produced nucleotide sequences that corresponded, with respect to the selected validation probes, to the results of classical Sanger sequencing. However, the NGS assay substantially reduced the laboratory effort to obtain the genetic information and provides the perquisites to be used in high throughput environments. In particular, the presented NGS assay is convenient for small up to large-scale setups. As mentioned in the methods section, a limitation of the present results applies to the identified genetic variants as only samples from Caucasian women were included. By contrast, the validity of gene selection and assay establishment is unlikely to be reduced by this selection chosen to remain within the financial limits of the present project.

Specifically, as observed previously ([@B116]), the comprehensive genetic information and the high throughput are reflected in the assay costs. Specifically, sequencing of the 77 genes in 72 DNA samples required approximately € 18,000 for the AmpliSeq^TM^ custom panel, € 5,500 for library preparation, € 700 for template preparation and € 700 for sequencing. Ten 318 sequencing chips cost around € 7,000 and in addition and basic consumables and laboratory supplies issued approximately € 800. With 7--8 barcoded samples loaded on ten chips, the expense to analyses the gene sequence for a single patient were around € 325. While NGS costs are likely to decrease in the near future ([@B135]), present assay establishment was therefore applied in DNA samples planned for future genotype versus phenotype association analysis, which required using DNA from patients of a pain-relevant cohort instead from a true random sample of healthy subjects.

As a result of the present assay development, a set of *d* = 77 genes was chosen as potentially relevant to persisting pain. The chosen set of genes differs from alternative proposals aiming at similar phenotypes ([@B161]; [@B254]). However, when analyzing these alternatives for mutual agreement, only limited overlap could be observed (**Figure [3](#F3){ref-type="fig"}**). This emphasizes that the genetic architecture of persisting pain is incompletely understood, and several independent lines of research can be pursued. Of note, the present set showed the largest agreement with a set of *d* = 539 genes identified empirically as relevant to pain and listed in the PainGenes database ([@B121])^[6](#fn06){ref-type="fn"}^ or recognized as causing human hereditary diseases associated with extreme pain phenotypes ([@B137]; [@B231]). Combining all proposals into a large panel was not an option due to the technical limitations of the IonTorrent restricting the panel size to 500 kb (pipeline version 5.6.2); therefore, further genes would need to be addressed in separate panels.

![Venn diagram ([@B236]) visualizing the intersections between the presently proposed set of human genes involved in modulating the risk or the clinical course of persisting pain ("Current set," green frame), and two alternative proposals \["Mogil" ([@B161]), blue frame and "Zorina-Lichtenwalter" ([@B254]), violet frame\]. In addition, a set of *d* = 539 genes identified empirically as relevant to pain and either listed in the PainGenes database ([http://www.jbldesign.com/](http://www.jbldesign.com/jmogil/enter.html)[jmogil/enter.html](http://www.jbldesign.com/jmogil/enter.html), [@B121]) or added because recognized as causing human hereditary diseases associated with extreme pain phenotypes, found to be regulated in chronic pain in at least three studies including human association studies, or being targets of novel analgesics. The number of shared genes between data sets is numerically shown in the respective intersections of the Venn diagram. The figure has been created using the R software package (version 3.4.2 for Linux; <http://CRAN.R-project.org/>, [@B184]) with the particular package "Vennerable" (Swinton J., <https://r-forge.r-project.org/R/?group_id=474>).](fphar-09-01008-g003){#F3}

In the present study sample, selected with a certain bias by using, as explained above for cost saving, clinical samples from only women and only Caucasians, a total of 659 genetic coding variants were found. Regardless of the sample preselection, 105 clinical associations (**Table [2](#T2){ref-type="table"}**) could be queried for the observed variants from openly obtainable data sources comprising (i) the Online Mendelian Inheritance in Man (OMIM^®^) database^[7](#fn07){ref-type="fn"}^, (ii) the NCBI gene index database^[8](#fn08){ref-type="fn"}^, the GeneCards database^[9](#fn09){ref-type="fn"}^ \[27\] and the "1000 Genomes Browser"^[10](#fn010){ref-type="fn"}^ (all accessed in December 2017). The observation of functional variants in the present cohort preselected for the absence of pain persistence is plausible as (i) variants can exert protective effects against chronic pain and (ii) most genetic variants identified so far exert only small effects on pain and the individual result of their functional modulations depends on their combined effects or from the sum of positive and negative effects on pain perception ([@B138]).

The selection of genes (**Table [1](#T1){ref-type="table"}**) relied on empirical evidence of their involvement in pain. For subset \#1 (*d* = 34), this had been shown for 33 genes in the original paper ([@B231]). As the hypothesis that persisting pain displays systemic features of learning and of neuronal plasticity ([@B149]) could be substantiated at a computational functional genomics level, the further gene (*PTPRZ1*, protein tyrosine phosphatase Z 1) can also be regarded as supported by prior knowledge to be included in the present set. The subset comprised, for example, genes associated with the mesolimbic dopaminergic system, i.e., *DRD1, DRD2, DRD3*, which code for dopamine receptors, and *TH*, which is the coding gene for the tyrosine hydroxylase, a metabolic restricting enzyme in dopaminergic pathways, which have been implicated in promoting chronic back pain ([@B79], [@B80]; [@B97]; [@B151]). Further 14 genes were involved in the circadian rhythm recognized as a modulatory factor in various pain conditions such as arthritis ([@B82]; [@B71]) and neuropathic pain ([@B72]). The subset further included three NMDA receptor genes (*GRIN1, GRIN2A*, and *GRIN2B*) known to be major players in a number of essential physiological functions including neuroplasticity ([@B35]). In addition, metabotropic glutamate receptors (mGluR) have been implemented in several chronic pain conditions. One subtype, mGluR5, coded by *GRM5*, is of particular interest in the context of pain conditions as recent studies showed a pro-nociceptive role of mGluR5 in models of chronic pain ([@B238]; [@B36]). Furthermore, genes associated with histaminergic signaling such as *HRH3* have been implicated in pain transmission ([@B90]) and analgesia ([@B92]).

The second subset of genes relied on a new PubMed search rather than on a previously published and hypothesis-based selection of candidate genes. A computational functional genomics analysis of this subset (details not shown) suggested its involvement in (i) immune processes and (ii) nitric oxide signaling. The genes annotated to the GO term "immune system process" included interleukin (IL1B, IL4, IL6, IL10) ([@B43]; [@B28]; [@B159]; [@B165]) and histocompatibility complex related (HLA-B) genes ([@B50]), which have been shown to be involved in immunological mechanisms of pain ([@B194]; [@B39]). This is also supported by published evidence for the further genes in this list, such as, *TNF* ([@B235]; [@B61]), *GCH1* ([@B198]) and *P2RX7* ([@B26]). The second major process group emerging from the functional genomics analysis of the key evidence for genetic modulation of clinical chronic pain was nitric oxide signaling, in particular metabolic processes, summarized in this context under the GO term "reactive oxygen species metabolic process" which includes the genes *IL6* ([@B40]), *TNF* ([@B40]; [@B103]), *ESR1* ([@B29]), *IL10* ([@B21]), *GCH1* ([@B103]; [@B252]), *IL1B* ([@B103]), *IL4* ([@B31]), *P2RX7* ([@B69]), *SOD2* ([@B62]). Furthermore, catecholamines including noradrenaline, adrenaline and dopamine have multiple functions in the brain and spinal cord including pain perception and processing ([@B45]). Catechol-*O*-methyltransferase, encoded by the *COMT* gene, is one of several enzymes that degrade dopamine, noradrenaline and adrenaline and has become one of the most frequently addressed genes in pain research ([@B163]).

Finally, subset \#3 (*d* = 30) consists of genes repeatedly shown to play a role in the genetic modulation of persisting pain in humans or, by contrast, included a few novel items only recently published in the context of pain. This included members of the transient receptor potential (TRP) family (*TRPA1, TRPM8, TRPV4*) that are expressed at nociceptors and which are well established players in the perception of pain via their excitation by chemical, thermal or mechanical stimuli ([@B30]). This similarly applies to the opioidergic system represented by the inclusion of the genes coding for the major opioid receptors (*OPRM1, OPRK1 OPRD1*), which have been associated with variations in pain or opioid response in various settings ([@B141]). The most important of this group, the μ-opioid receptor encoded by the *OPRM1* gene, carriers several variants of which the 118 A\>G (rs1799971) has been studied most extensively since the early description of its association with a functional phenotype in humans ([@B145]).

Almost half of the present sets of genes were chosen based on a computational functional genomics analysis that attributed persisting pain to GO processes of "learning or memory" and "nervous system development" ([@B231]) as likely to reflect systemic features of persisting pain. This implied a functional bias and therefore, the present set of *d* = 77 genes (**Figure [4](#F4){ref-type="fig"}**) was analyzed whether this bias prevailed when comparing it with the alternative sets of human genes proposed to modulate persisting pain ([@B161]; [@B254]). As applied previously ([@B131]), the biological roles of the set of *d* = 77 genes were queried from the Gene Ontology knowledgebase (GO)^[11](#fn011){ref-type="fn"}^ ([@B6]) where the knowledge about the biological processes, the molecular functions and the cellular components of genes is formulated using a controlled and clearly defined vocabulary of GO terms. Particular biological roles of the set of *d* = 77 genes, among all human genes, were analyzed by means of over-representation analysis (ORA). This compared the occurrence of the particular GO terms associated with the present set of genes with their expected occurrence by chance ([@B7]). In contrast to enrichment analysis, any quantitative criteria such as gene expression values are disregarded ([@B7]). The analyses were performed using our R library "dbtORA" ([@B131])^[12](#fn012){ref-type="fn"}^ on the R software environment (version 3.4.2 for Linux; [@B184])^[13](#fn013){ref-type="fn"}^.

![Top--down representation of the annotations (GO terms) representing the taxonomy of the functional differences between the set of *d* = 77 genes included in the proposed NGS panel of persisting pain and two alternative proposals of genes modulating persisting pain in humans ([@B161]; [@B254]). The figure represents the results of an over-representation analysis of the present set of *d* = 77 genes against the reference comprising the set intersection of the alternative gene lists. A *p*-value threshold of 0.01 and Bonferroni α-correction were applied. Significant terms are shown as colored circles with the number of member genes, the number of expected genes by change and the significance of the deviation of the observed from the expected number of genes indicated (yellow = headline, red = significant term, blue = significant term located as a leave at the end of a taxonomy in the polyhierarchy). The graphical representation follows the standard of the GO knowledgebase, where GO terms are related to each other by "is-a," "part-of," and "regulates" relationships forming a polyhierarchy organized in a directed acyclic graph (DAG, [@B226]). The figure has been created using our R library "dbtORA" (<https://github.com/IME-TMP-FFM/dbtORA>, [@B131]) on the R software package (version 3.4.2 for Linux; <http://CRAN.R-project.org/>, [@B184]) and the freely available graph visualization software GraphViz (<http://www.graphviz.org>, [@B65]).](fphar-09-01008-g004){#F4}

Surprisingly, the results of this analysis indicated that the functional bias of the present gene set toward "learning or memory" (GO:0007611) and "nervous system development" (GO:0007399) was not maintained against the alternative gene sets. Instead, a few more general GO terms such as "behavior" ("single organism behavior," GO:0044708), or "response to organic cyclic compound" (GO:0014070) and response to alkaloid (GO:0043279), which could be identified as morphine and cocaine when repeating the analysis with a less conservative α-correction (further details not shown), were overrepresented, as well as the pain specific term "sensory perception of pain" (GO:0019233). A possible explanation that the selection bias of the present gene set was not maintained when comparing it with alternative proposals is that the two biological processes, "learning or memory" and "nervous system development," reflect indeed an important biological function of persisting pain and even when choosing candidate genes without having these processes in mind as for the alternative gene sets, they are nevertheless included. This may be regarded as support for the present gene set as suitable candidates for future association studies with persisting pain phenotypes.

Although the present gene set has been assembled with a focus of a relevance to pain, many of its members have pharmacological implications. Specifically, 58 of the 77 genes (75%) have been chosen as targets of analgesics, approved or under current clinical development (**Table [3](#T3){ref-type="table"}**). Moreover, several of the genes in the present NGS panel have been implicated in pharmacogenetic modulations of drug effects (**Table [4](#T4){ref-type="table"}**). Possibly the most widely studied gene in analgesic research is *OPRM1* because coding for the primary target of opioids ([@B178]). Several polymorphisms have been described in *OPRM1*, among which the best characterized may be rs1799971 (*OPRM1* 118A\>G) that leads to an asparagine to aspartate substitution at the extracellular terminal of the receptor protein ([@B9]). May studies have addressed this variant (for reviews, see [@B239]; [@B217]). Summarizing its effects, the variant is associated with decreased receptor expression and signaling efficiency ([@B170]) which leads to reproducibly reduced pharmacodynamic effects in human experimental settings while the effect size seems insufficient to be a major factor of opioid response in clinical settings, despite several reports of modulations of opioid demands or side effects. For example, subjects carrying the 118A\>G variant were found to have a reduced response to morphine treatment ([@B95]), reduced analgesic response to alfentanil ([@B171]) and demanded higher doses of morphine for pain relief ([@B112]; [@B95]). However, the importance of this variant seems to be comparatively high in patients with an Asian ethnic background, which might be related to the higher allelic frequency as compared to other ethnicities. *COMT* is a key modulator of dopaminergic neurotransmission and in the signaling response to opioids The Val158Met polymorphism (rs4680) causes an amino acid substitution in the enzyme, which reduced the enzyme active to a forth ([@B178]). Carriers of the homozygous Met/Met variant had lower morphine requirements than those with a the wild type *COMT* ([@B185]). Furthermore, a modulation of the effects of *TRPV1* targeting analgesics is supported by observations that intronic *TRPV1* variants were associated with insensitivity to capsaicin ([@B177]) while the coding *TRPV1* variant rs8065080 was associated with altered responses to experimentally induced pain([@B108]). Moreover, gain-of-function mutations in *TRPV1* have been associated with increased pain sensitivity ([@B10]), for which *TRPV1* antagonists would enable a specific pharmacogenetics-based personalized cure.

###### 

Current targeting of the genes included in the proposed NGS panel of persisting pain by novel drugs that are currently under active clinical development and include analgesia as the main clinical target or at least as one of the intended clinical indication.

  Gene         Status                     Drug                        Action                                              Company
  ------------ -------------------------- --------------------------- --------------------------------------------------- -----------------------------------------
  *ABHD12*     --                         --                          --                                                  --
  *ABHD16A*    --                         --                          --                                                  --
  *ABHD6*      Preclinical                Benzylpiperidin methanone   Acylamino-Acid-Releasing Enzyme                     Scripps Research Institute
  *ADCY1*      Under Active Development   NB-001                      Adenylate Cyclase Inhibitors                        Forever Cheer International
  *ADRB2*      Phase II/III               Gencaro                     Signal Transduction Modulators                      ARCA
  *BDNF*       Phase I                    CXB-909                     Nerve Growth Factor (NGF) Enhancers                 Krenitsky
  *CACNG2*     Preclinical                Hanfangchin                 Calcium Channel Blockers                            Millenia Hope Kaken
  *CDK5*       Biological Testing         Litvinolin                  CDK5/p25 Inhibitors                                 Hong Kong University
  *CHRNB2*     Biological Testing         Epiboxidine                 Nicotinic alpha4beta2 Receptor Agonists             Pfizer
  *CNR1*       Registered                 Epidiolex                   Cannabinoid Receptor Agonists                       InSys Therapeutics
  *COMT*       Clinical                   Nitecapone                  Catechol-*O*-Methyl Transferase (COMT) Inhibitors   Orion
  *CSF1*       --                         --                          --                                                  --
  *DLG4*       Preclinical                AB-125                      Protein Inhibitors                                  Lundbeck University of Copenhagen
  *DRD1*       Phase II/III               Ecopipam                    Dopamine D1 Receptor (DRD1) Antagonists             Merck & Co.
  *DRD2*       Phase II/III               Sarizotan hydrochloride     Dopamine D2 Receptor (DRD2) Antagonists             Newron
  *DRD3*       Phase II                   Brilaroxazine               D3 Receptor (DRD3) Agonists                         Reviva Pharmaceuticals
  *DRD4*       Biological Testing         Mesulergine hydrochloride   Dopamine Receptor Agonists                          Novartis
  *EGR1*       Phase II                   Brivoligide                 EGR1 Expression Inhibitors                          Adynxx
  *ESR1*       Phase II                   Zindoxifene                 Selective Estrogen Receptor Modulators              Evonik
  *FAAH*       Phase I/II                 Minerval                    Fatty Acid Amide Hydrolase (FAAH) Inhibitors        Scripps Research Institute
  *FKBP5*      Phase II                   Barusiban                   Oxytocin Receptor Antagonist                        Ferring
  *FOS*        Registered                 Macrilen                    FOS Expression Enhancers                            Strongbridge Biopharma
  *FYN*        Phase II                   Bafetinib                   Fyn Kinase Inhibitors                               Nippon Shinyaku
  *GABRA5*     Phase III                  Ganaxolone                  GABA(A) Receptor Modulators                         Marinus Pharmaceuticals
  *GALR2*      Preclinical                NAX-810-2                   GAL2 Receptor Ligands                               NeuroAdjuvants
  *GCH1*       --                         --                          --                                                  --
  *GDNF*       Phase II                   Edonerpic maleate           Signal Transduction Modulators                      Toyama
  *GFRA1*      --                         --                          --                                                  --
  *GPR132*     --                         --                          --                                                  --
  *GRIN1*      Phase II                   Dimiracetam                 Signal Transduction Modulators                      Metys Pharmaceuticals
  *GRIN2A*     Phase I                    Dexanabinol                 NMDA Receptor Antagonists                           e-Therapeutics Pharmos
  *GRIN2B*     Phase I                    Gacyclidine                 NMDA Receptor Antagonists                           INSERM
  *GRM5*       Phase II                   Mavoglurant                 Signal Transduction Modulators                      Novartis
  *HCN2*       Clinical                   Ivabradine                  Adrenoceptor Antagonists                            Servier
  *HLA-DQB1*   --                         --                          --                                                  --
  *HLA-DRB1*   --                         --                          --                                                  --
  *HRH3*       Phase I                    Immethridine                Histalean                                           Abbott
  *HTR1A*      Phase II                   Eltoprazine hydrochloride   5-HT1A Receptor Agonists                            Elto Pharma
  *HTR2A*      Phase II                   Midomafetamine              5-HT2 Receptor Agonists                             Assoc
  *IL10*       Phase II                   BT-063                      Signal Transduction Modulators Anti-IL-10           Biotest AG
  *IL1B*       Phase III                  Resunab                     IL-1beta Inhibitors                                 Corbus
  *IL1R2*      --                         --                          --                                                  --
  *IL4*        --                         --                          --                                                  --
  *IL6*        Preclinical                Azintrel                    Signal Transduction Modulators Anti-IL-6            Jazz Pharmaceuticals
  *KCNS1*      Preclinical                Crotamine                   Voltage-Gated K(V) Channel Blockers                 Celtic Biotech
  *KIT*        Phase II                   Vatalanib succinate         KIT (C-KIT) Inhibitors                              Novartis
  *LTB4R*      Phase II                   Coversin                    Signal Transduction Modulators                      Akari Therapeutics
  *LTB4R2*     Phase II                   Coversin                    Signal Transduction Modulators                      Akari Therapeutics
  *NF1*        --                         --                          --                                                  --
  *NGF*        Phase III                  Tanezumab                   Anti-Nerve Growth Factor (NGF)                      Pfizer
  *NTF4*       --                         --                          --                                                  --
  *NTRK1*      Phase II                   Danusertib                  NTRK1 Inhibitors                                    Pfizer
  *OPRD1*      Preclinical                Metenkephalin               Delta-Opioid Receptor Agonists                      TNI Pharmaceuticals
  *OPRK1*      Phase III                  Morphine glucuronide        Opioid Receptor Agonists                            PAION
  *OPRM1*      Registered                 Naltrexone                  mu-Opioid Receptor Antagonists                      Pfizer
  *OXT*        Phase II                   Barusiban                   Oxytocin Receptor Antagonist                        Ferring
  *P2RX7*      Preclinical                BIL-06v                     Anti-P2RX7                                          Biosceptre International
  *PLCB1*      Biological Testing         Vinaxanthone                Signal Transduction Modulators                      Roche
  *PRKCG*      Phase III                  Rydapt                      Protein Kinase C (PKC) Inhibitors                   Yeda
  *PRNP*       --                         --                          --                                                  --
  *PTN*        --                         --                          --                                                  --
  *PTPRZ1*     --                         --                          --                                                  --
  *RELN*       Preclinical                IAIPs                       Serine Protease Inhibitors                          ProThera Biologics
  *RET*        Phase II                   Danusertib                  Ret (RET) Inhibitors                                Pfizer
  *RUNX1*      --                         --                          --                                                  --
  *S100B*      --                         --                          --                                                  --
  *SCN9A*      Phase III                  Priralfinamide              Voltage-Gated Sodium Channel Blockers               Newron
  *SLC6A4*     Phase II                   Litoxetine                  Signal Transduction Modulators                      Sanofi
  *SOD2*       Phase II                   Avasopasem manganese        Superoxide Dismutase (SOD) Mimetics                 MetaPhore
  *TH*         --                         --                          --                                                  --
  *TLR4*       Phase II                   Eritoran tetrasodium        Toll-Like Receptor 4 (TLR4) Antagonists             Eisai
  *TNF*        Phase III                  Givinostat hydrochloride    TNF-alpha Release Inhibitors                        Italfarmaco
  *TRPA1*      Phase II                   Cannabidivarin              TRPA1 Agonists                                      GW Pharmaceuticals
  *TRPM8*      Phase II                   Cannabidivarin              TRPM8 Antagonists                                   GW Pharmaceuticals
  *TRPV1*      Phase I/II                 Resiniferatoxin             TRPV1 (Vanilloid VR1 Receptor) Agonists             Icos
  *TRPV4*      Phase II                   GSK-2798745                 TRPV4 Antagonists                                   GlaxoSmithKline
  *TSPO*       Clinical                   \[11C\]CB-184               Translocator Protein (TSPO) Ligands                 Tokyo Metrop Geriatr Hosp Inst Gerontol

The information was queried from the Thomson Reuters Integrity database at

https://integrity.thomson-pharma.com

on July 11, 2018.

###### 

Summary of variants in genes included in the proposed NGS panel of persisting pain, that have been implicated in a pharmacogenetic context to modulate the effects of drugs administered for the treatment of pain or as disease modifying therapeutics in painful disease.

  Modulated process             Gene      Variant              Affected drug     Findings                                                                                                                                    Reference
  ----------------------------- --------- -------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------- -----------
                                                                                                                                                                                                                             
  G protein coupled signaling   *COMT*    rs4680 (Val158Met)   Morphine          Carriers of val/val and val/met genotype required higher morphine dose compared to carriers of met/met genotype                             [@B187]
                                *DRD2*    rs6275               Heroine           Polymorphism is associated with decreased likelihood of headache disorders                                                                  [@B20]
                                *DRD4*    rs1800955            Heroine           Polymorphism had lower pain threshold versus CC/CT controls                                                                                 [@B86]
                                *OPRM1*   rs1799971 (A118G)    Various opioids   Tendency toward increased pain in dose-dependent manner with the μ-opioid receptor variant 118G                                             [@B140]
                                *OPRK1*   rs1051660            Morphine          Patients with the polymorphism and cancer-related pain may require a reduced dose escalation of morphine                                    [@B23]
  Neurotransmitters             *BDNF*    rs6265               Various opioids   Polymorphism is associated with decreased likelihood of headache disorders                                                                  [@B20]
                                *HTR2A*   rs12584920           Various opioids   Increased likelihood of having chronic widespread pain                                                                                      [@B166]
  Ion Channels                  *TRPV1*   7 intronic SNPs      Capsaicin         TRPV1 polymorphisms had only 50% of the mRNA and protein expression levels of normally sensing subjects                                     [@B177]
  Proinflammatory Cytokines     *IL6*     rs1800795            Etanercept        Polymorphism is associated with increased response to adalimumab, etanercept or infliximab in people with painful Arthritis                 [@B37]
  Other                         *ESR1*    rs2234693            Leflunomide       Polymorphism is associated with increased response to leflunomide in women with painful Arthritis                                           [@B52]
                                *FAAH*    rs2295632            Various opioids   Polymorphism is associated with increased risk of Respiratory Insufficiency                                                                 [@B8]
                                *TLR4*    rs4986790            Methotrexate      Polymorphism associated with increased risk of adverse drug events when treated with folic acid and methotrexate in people with Arthritis   [@B114]
                                *TNF*     rs361525             Infliximab        Polymorphism is associated with increased response to infliximab in people with painful Arthritis                                           [@B152]

The information was derived by literature search and by querying the Pharmacogenetics Research Network/Knowledge base at

http://www.pharmgkb.org

(accessed in July 2018). Only key or example references are given.

Conclusion
==========

The breakthrough in mapping the whole human genome ([@B122]; [@B237]) along with genome wide association studies (GWAS) has led to rapid advances in the knowledge of the genetic bases of human diseases ([@B243]). Genetic research in pain medicine has directed to the recognition of genes in which variants influence pain behavior, post-operative drug requirements, and the temporal developments of pain toward persistence ([@B98]). While many candidate gene association studies have identified multiple genes relevant for pain phenotypes ([@B59]), pain related genetic studies have so far been owned by investigations of a limited number of genes. Roughly ten genes or gene complexes account for over half of the extant findings and several of these candidate gene associations have held up in replication ([@B161]). The selection of variants has been limited and they have been addressed in most studies repeatedly, leading to the perception that genetic research in pain produces often unsatisfactory results ([@B160]). However, this may soon change with the arise of new technologies. In this manuscript, we present a validated NGS assay for a set of 77 genes supported by empirical evidence and computational functional genomics analyses as relevant factors modulating the risk for persisting pain or its clinical picture.
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